Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated:  9/22/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated: 9/22/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Stem Cell Transplant for Hematologic Diseases
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H
Status: Enrolling
Updated:  9/23/2015
Texas Children's Hospital
mi
from
Houston, TX
Stem Cell Transplant for Hematologic Diseases
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H
Status: Enrolling
Updated: 9/23/2015
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Stem Cell Transplant for Hematologic Diseases
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H
Status: Enrolling
Updated:  9/23/2015
Methodist Hospital
mi
from
Houston, TX
Stem Cell Transplant for Hematologic Diseases
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H
Status: Enrolling
Updated: 9/23/2015
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
University of Chicago
mi
from
Chicago, IL
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
NorthShore University HealthSystem
mi
from
Evanston, IL
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Capital Federal,
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Capital Federal,
Click here to add this to my saved trials
Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
Safety and Efficacy (Phase II) Study of Concurrent Cetuximab Plus Conformal Thoracic Radiotherapy in (Poor Prognosis) Patients With Inoperable or Unresectable, Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
Status: Enrolling
Updated:  9/23/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
Safety and Efficacy (Phase II) Study of Concurrent Cetuximab Plus Conformal Thoracic Radiotherapy in (Poor Prognosis) Patients With Inoperable or Unresectable, Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
Status: Enrolling
Updated: 9/23/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Cancer Center of Kansas
mi
from
Wichita, KA
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Kentucky Cancer Clinic
mi
from
Hazard, KY
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Kentucky Cancer Clinic
mi
from
Hazard, KY
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Annapolis Oncology Center
mi
from
Annapolis, MD
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Annapolis Oncology Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
North Canton Medical Clinic Center
mi
from
Canton, OH
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
North Canton Medical Clinic Center
mi
from
Canton, OH
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Guthrie Clinic, Ltd.
mi
from
Sayre, PA
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Guthrie Clinic, Ltd.
mi
from
Sayre, PA
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Rhode Island Hospital
mi
from
Providence, RI
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Blue Ridge Cancer Care
mi
from
Christiansburg, VA
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Blue Ridge Cancer Care
mi
from
Christiansburg, VA
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Providence Western Washington Oncology
mi
from
Lacey, WA
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Providence Western Washington Oncology
mi
from
Lacey, WA
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Acrc/Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Acrc/Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Palm Beach Cancer Institute, LLC
mi
from
West Palm Beach, FL
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Palm Beach Cancer Institute, LLC
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Clintell, Inc.
mi
from
Skokie, IL
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Clintell, Inc.
mi
from
Skokie, IL
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
North Mississippi Hematology And Oncology Associates, Ltd
mi
from
Tupelo, MS
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
North Mississippi Hematology And Oncology Associates, Ltd
mi
from
Tupelo, MS
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Kaiser Permanente Oncology/Hematology
mi
from
Portland, OR
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Kaiser Permanente Oncology/Hematology
mi
from
Portland, OR
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Cancer Center At Cookeville Regional Medical Center
mi
from
Cookeville, TN
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Cancer Center At Cookeville Regional Medical Center
mi
from
Cookeville, TN
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
University of Tennessee Cancer Institute
mi
from
Memphis, TN
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
University of Tennessee Cancer Institute
mi
from
Memphis, TN
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Fortaleza,
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Fortaleza,
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Agajanian Institute Of Hematology And Oncology
mi
from
Downey, CA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Agajanian Institute Of Hematology And Oncology
mi
from
Downey, CA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Sharp Clinical Oncology Research
mi
from
San Diego, CA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
James Graham Brown Cancer Center
mi
from
Louisville, KY
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
3912 Taubman Center
mi
from
Ann Arbor, MI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
3912 Taubman Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Univ Of Ark For Med Sci
mi
from
Little Rock, AR
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Univ Of Ark For Med Sci
mi
from
Little Rock, AR
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Va Ct Healthcare System
mi
from
West Haven, CT
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Va Ct Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Medical Specialists Of Palm Beaches
mi
from
Lake Worth, FL
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Medical Specialists Of Palm Beaches
mi
from
Lake Worth, FL
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Mcguire Dvamc
mi
from
Richmond, VA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Mcguire Dvamc
mi
from
Richmond, VA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
University of Wisconsin
mi
from
Madison, WI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Caba,
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Caba,
Click here to add this to my saved trials
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Status: Enrolling
Updated:  9/23/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Status: Enrolling
Updated: 9/23/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Texas Oncology-Abilene
mi
from
Abilene, TX
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Texas Oncology-Abilene
mi
from
Abilene, TX
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Texas Oncology-Beaumont
mi
from
Beaumont, TX
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Texas Oncology-Beaumont
mi
from
Beaumont, TX
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Us Oncology Central Pharmacy
mi
from
Fort Worth, TX
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Us Oncology Central Pharmacy
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Rosario,
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Rosario,
Click here to add this to my saved trials